King of Prussia, Pennsylvania — March 5, 2026 — Leads & Copy — Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical-stage siRNA biopharmaceutical company, announced that CEO and Chairman of the Board Robert Bitterman will provide an overview of the company’s INTASYL siRNA platform and discuss recent clinical progress and priorities, followed by a live Q&A.
Phio’s presentation and live Q&A will take place on Monday, March 9, 2026, at 10 AM EDT in the live Virtual Non-Deal Roadshow Series hosted by Renmark Financial Communications Inc.
Phio’s lead clinical candidate, PH-762, is being evaluated as an intratumoral therapy in cutaneous squamous cell carcinoma (cSCC), melanoma, and Merkel cell carcinoma.
In its Phase 1b trial, Phio reported that 22 patients completed treatment across five dose-escalation cohorts, with no dose-limiting toxicities or serious adverse events. The company also reported a pathological response rate in cSCC across all dosing cohorts of approximately 65%, including an 85% pathological response (6 of 7 patients) in the highest-dose cohort.
Phio has indicated that FDA engagement regarding next-stage clinical development is targeted for the second quarter of 2026 and has reported cash and cash equivalents projected to sustain operations into the first half of 2027.
According to Bitterman, the company looks forward to sharing why they believe INTASYL represents a differentiated approach to immuno-oncology and discussing their strategy for PH-762 as they plan for the next stage of development.
A replay of the event may be accessed on the Renmark Financial Communications Inc. website.
Phio Pharmaceuticals Corp. is focused on immuno-oncology therapeutics, advancing its INTASYL® gene silencing technology. Phio’s INTASYL compounds are designed to enhance the body’s immune cells to more effectively kill cancer cells. Phio’s lead clinical program is an INTASYL compound, PH-762, that silences the PD-1 gene implicated in various forms of skin cancer. The Phase 1b trial (NCT# 06014086) is evaluating PH-762 for the treatment of cutaneous squamous cell carcinoma, melanoma and Merkel cell carcinoma. PH-762 is a potential non-surgical treatment for skin cancers.
REGISTER HERE: Renmark Virtual Non-Deal Roadshow: NASDAQ – PHIO | Event Registration | Renmark Financial Communications
Please Note: If the link does not work, please copy and paste into your browser. To ensure smooth connectivity, please access the link above using the latest version of Google Chrome.
Source: Phio Pharmaceuticals Corp.
